CIBy Calypso Research7 min read

Cigna Corporation (CI) Q4 2025 Earnings Analysis

Cigna-tion of Earnings: $72.5B and a 4.7% Boost

Key Takeaways

Cigna Corporation (CI) reported Q4 2025 earnings with revenue of $72.5B, representing a +10.4% year-over-year change. The stock moved +4.7% on earnings day.

The bull case: Cigna’s proactive shift to a transparent, rebate-free PBM model, combined with high-growth specialty & care assets and disciplined underwriting in Cigna Healthcare, supports sustained double-digit EPS growth with manageable regulatory and tax headwinds.

The bear case: Regulatory and legislative pressure on PBM economics, potential slower-than-hoped adoption of the new model, persistent elevated medical cost trends, and softer cash flow conversion could undermine Cigna’s ability to deliver its 10–14% long-term EPS growth algorithm.

Financial Highlights

  • Revenue: $72.5B (+10.4% YoY)
  • Gross Profit: $5.6B (7.7% margin, -2.2% YoY)
  • Operating Income: $2.1B (3.0% margin, -0.3% YoY)
  • Net Income: $1.2B
  • TTM Revenue: $275.0B

Stock Performance

  • Earnings Day Move: +4.7%
  • Year-to-Date: +1.5%
  • 1-Year Return: -5.9%
  • vs. S&P 500 (since earnings): +6.5%
  • vs. Nasdaq (since earnings): +9.6%

View live CI data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Cigna Corporation's Q4 2025 earnings call:

PBM Model Transformation, FTC Settlement, and Long‑Term Margin Algorithm

Sentiment: Positive

"from a big picture standpoint, we believe the margin profile will be similar and therefore, we believe the underlying growth algorithm for the pharmacy benefit services portion of our portfolio will remain intact to be similar as we get through this innovation." — David Cordani
"no change in the direction as a result of the settlement. No change in our direction as a result of what we saw in the legislation that passed this week." — David Cordani

Adoption Ramp, Client Choice, and Regulatory Risk Around the New Rebate‑Free PBM Model

Sentiment: Positive

"The entire Cigna Healthcare fully insured book will be adopting the new model in 2027. We expect at least 50% of our EverNorth business will adopt the model by year-end 2028." — Brian Evanko
"it will be our standard offering. It will be our lead offering in 2028... Third, there is no liability that we assume if the adoption rate is above or below that. We will lead the market. We will support this with marketing dollars because we are convicted and believe that this is the future of pharmacy benefit services." — David Cordani

Tax Rate Impact of Moving the GPO to the U.S. and Overall PBM Economics

Sentiment: Mixed

"At the macro level, you could think about an outside impact to the effective tax rate of our organization of up to 1%. Over time, because there's a phase-in here. If unmitigated." — David Cordani
"the move of our GPO capabilities from Switzerland to the US is unrelated to the new rebate-free model... there's some elements of the FTC agreement that are unrelated to it. But the launch plan for our rebate-free model is unchanged as a result of the agreement." — Brian Evanko

2026 Cigna Healthcare MCR Outlook and Limited Visible Margin Progress

Sentiment: Mixed

"our 2026 MCR outlook incorporates the pricing actions we've taken across stop loss and the individual exchange businesses as well as the assumption that the cost trend environment remains elevated." — Ann Dennison
"Items that increase the MCR on a comparative basis, if you recall, the 2025 MCR benefited from several one-time items in our individual business, both of which impact the jump-off point for the year and tempered the year-over-year MCR improvement... and lastly, I'd say sort of overall, our assumptions incorporate appropriate prudence given the continued elevated cost environment." — Ann Dennison

PBM Revenue Recognition and Accounting Under the Fee‑Based Model

Sentiment: Mixed

"at this point in time, the FTC agreement will not impact our '27 financial outlook... our long-term growth algorithm for PBS remains intact as we move through the transitional period here." — Brian Evanko
"at this point in time, we do not expect there to be changes in the way that our revenue is being recognized in the PBS segment. Even with the transition to a fee-based model as opposed to a spread or rebate-oriented model that we have today." — Brian Evanko

Bull Case

Cigna’s proactive shift to a transparent, rebate-free PBM model, combined with high-growth specialty & care assets and disciplined underwriting in Cigna Healthcare, supports sustained double-digit EPS growth with manageable regulatory and tax headwinds.

Bear Case

Regulatory and legislative pressure on PBM economics, potential slower-than-hoped adoption of the new model, persistent elevated medical cost trends, and softer cash flow conversion could undermine Cigna’s ability to deliver its 10–14% long-term EPS growth algorithm.

Looking Ahead

With revenue growing +10.4% year-over-year, the key question is whether Cigna Corporation can sustain this growth trajectory, particularly around pBM Model Transformation, FTC Settlement, and Long‑Term Margin Algorithm. With operating margins at 3.0%, margin trends will remain a focal point. The market's positive reaction on earnings day suggests confidence in management's direction, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Cigna Corporation's revenue in Q4 2025?

Cigna Corporation reported Q4 2025 revenue of $72.5B, representing a +10.4% year-over-year change.

Did Cigna Corporation beat earnings expectations in Q4 2025?

The stock rose +4.7% on earnings day, suggesting the results met or exceeded market expectations. The current bull case centers on: Cigna’s proactive shift to a transparent, rebate-free PBM model, combined with high-growth specialty & care assets and disciplined underwriting in Cigna Healthcare, supports sustained double-digit EPS growth with manageable regulatory and tax headwinds.

What is the bull case for CI stock?

The bull case for CI centers on: Cigna’s proactive shift to a transparent, rebate-free PBM model, combined with high-growth specialty & care assets and disciplined underwriting in Cigna Healthcare, supports sustained double-digit EPS growth with manageable regulatory and tax headwinds.

What is the bear case for CI stock?

The bear case for CI centers on: Regulatory and legislative pressure on PBM economics, potential slower-than-hoped adoption of the new model, persistent elevated medical cost trends, and softer cash flow conversion could undermine Cigna’s ability to deliver its 10–14% long-term EPS growth algorithm.

How has CI stock performed since its Q4 2025 earnings?

CI moved +4.7% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +6.5% since earnings. Year-to-date, the stock has returned +1.5%.

Browse all 400+ earnings reports →

Learn More

Analyze CI in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Cigna Corporation and 400+ other stocks, explore the full platform.

Open CI on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.